☆ 4.1 Article

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial

JOURNAL OF BONE ONCOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Pathology

Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases

Li Yang et al.

Summary: Denosumab-treated GCTB exhibits histological changes such as depletion of giant cells and intralesional bone deposition, which may lead to diagnostic difficulties. The post-therapy tumors have a similar mutation profile to classic GCTB but significantly differ morphologically. Awareness of the features of DT-GCTB and conducting immunohistochemical and molecular studies for histone H3 mutations are important in its assessment.

ANNALS OF DIAGNOSTIC PATHOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

Denosumab for central giant cell granuloma in an Australian tertiary paediatric centre

Joel A. Vanderniet et al.

Summary: The efficacy and safety of denosumab treatment for children with CGCG were evaluated. The results showed that denosumab reduced metabolic activity of the lesions but the risk of metabolic recurrence remained. PET imaging was effective for monitoring treatment response and early detection of recurrence. The incidence of rebound hypercalcaemia was high in pediatric patients.

BONE (2022)

Add to Collection

Article Oncology

Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications

Cindy Y. Jiang et al.

Summary: In the treatment of giant cell tumors of the bone (GCTB), increasing the interval of denosumab dosing provides similar tumor control compared to standard dosing and reduces the number of bone toxicity events. However, larger studies are needed to determine the optimal dosing interval and its impact on efficacy, toxicity, and healthcare expense.

ONCOLOGIST (2022)

Add to Collection

Review Oncology

Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence

Aneta Maria Borkowska et al.

Summary: The widely accepted local therapy for extremity giant cell tumor of bone is surgery, and denosumab is a relevant treatment option for advanced cases. Surgical curettage is successful for most localized lesions, but denosumab can achieve long-term clinical and radiological remission for primary unresectable lesions or metastases.

CANCERS (2022)

Add to Collection

Article Medicine, Research & Experimental

Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Ethan Basch et al.

Summary: A composite grading algorithm has been developed to provide single numerical grades for adverse events assessed via the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, and can be useful in analyses and reporting. The algorithm was refined through a five-step process and was found to perform well and comparably to individual item scores on validity, reliability, sensitivity, and between-arm delineation.

CLINICAL TRIALS (2021)

Add to Collection

Review Oncology

Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls

Hengyuan Li et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Oncology

In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid

Isao Shibuya et al.

PATHOLOGY & ONCOLOGY RESEARCH (2019)

Add to Collection

Article Oncology

Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study

Sant Chawla et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Medicine, Research & Experimental

Norcantharidin modulates the miR-30a/Metadherin/AKT signaling axis to suppress proliferation and metastasis of stromal tumor cells in giant cell tumor of bone

Feiyan Chen et al.

BIOMEDICINE & PHARMACOTHERAPY (2018)

Add to Collection

Article Oncology

Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone

Jacob Engellau et al.

WORLD JOURNAL OF SURGICAL ONCOLOGY (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Downregulation of miR-223 and miR-19a induces differentiation and promotes recruitment of osteoclast cells in giant-cell tumor of the bone via the Runx2/TWIST-RANK/RANKL pathway

Zong-Yuan Jiang et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)

Add to Collection

Review Oncology

Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone

Czar Louie Gaston et al.

CLINICAL SARCOMA RESEARCH (2016)

Add to Collection

Editorial Material Oncology

The growing problem of benign connective tissue tumours

David M. Thomas

LANCET ONCOLOGY (2015)

Add to Collection

Article Oncology

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

David Henry et al.

SUPPORTIVE CARE IN CANCER (2014)

Add to Collection

Article Medical Informatics

Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation

Dominik Peus et al.

BMC MEDICAL INFORMATICS AND DECISION MAKING (2013)

Add to Collection

Letter Oncology

Re: Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of three pivotal, randomised, phase 3 trials

Kazuhiro Araki et al.

EUROPEAN JOURNAL OF CANCER (2013)

Add to Collection

Editorial Material Oncology

Denosumab treatment of giant cell tumour of bone

Maurice Balke

LANCET ONCOLOGY (2013)

Add to Collection

Article Oncology

Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study

Sant Chawla et al.

LANCET ONCOLOGY (2013)

Add to Collection

Review Oncology

Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases

Kaitlin Koo et al.

SUPPORTIVE CARE IN CANCER (2013)

Add to Collection

Article Oncology

Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

Daniel G. Branstetter et al.

CLINICAL CANCER RESEARCH (2012)

Add to Collection

Article Oncology

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

David H. Henry et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Article Health Care Sciences & Services

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases

Jipan Xie et al.

JOURNAL OF MANAGED CARE PHARMACY (2011)

Add to Collection

Article Oncology

Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone

Maurice Balke et al.

BMC CANCER (2010)

Add to Collection

Editorial Material Oncology

Denosumab: a breakthrough in treatment of giant-cell tumour of bone?

Maurice Balke et al.

LANCET ONCOLOGY (2010)

Add to Collection

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

Article Endocrinology & Metabolism

Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: A case-control study

Lung Fung Tse et al.

BONE (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.